

Role of Continuous Glucose Monitoring in Diabetic Patients at High Cardiovascular Risk: an Expert-based Multidisciplinary Delphi Consensus

Carlo Mario

AOU Careggi and University of Florence

Stefano Genovese (✉ stefano.genovese@cardiologicomonzino.it)

Centro Cardiologico Monzino IRCCS

Gaetano Antonio Lanza

Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore

Edoardo Mannucci

AOU Careggi and University of Florence

Giancarlo Marezi

Centro Cardiologico Monzino IRCCS

Edoardo Sciatti

ASST Papa Giovanni XXIII

Dario Pitocco

Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore

Research Article

Keywords: Delphi method, continuous glucose monitoring, cardiovascular outcome, time in range, glycaemic variability, glucometrics

Posted Date: March 22nd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1446808/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background. Continuous glucose monitoring (CGM) shows in more detail the glycaemic pattern of diabetic subjects and provides several new parameters (“glucometrics”) to assess patients’ glycaemia and consensually guide treatment. A better control of glucose levels might result in improvement of clinical outcome and reduce disease complications. This study aimed to gather an expert consensus on the clinical and prognostic use of CGM in diabetic patients at high cardiovascular risk or with heart disease.

Methods. A list of 22 statements concerning type of patients who can benefit from CGM, prognostic impact of CGM in diabetic patients with heart disease, CGM use during acute cardiovascular events and educational issues of CGM were developed. Using a two-round Delphi methodology, the survey was distributed online to 42 Italian experts (21 diabetologists and 21 cardiologists) who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement.

Results. Forty experts (95%) answered the survey. Every statement achieved a positive consensus. In particular, the panel expressed the feeling that CGM can be prognostically relevant for every diabetic patient (70%) and that is clinically useful also in the management of those with type 2 diabetes not treated with insulin (87.5%). The assessment of time in range (TIR), glycaemic variability (GV) and hypoglycaemic/hyperglycaemic episodes were considered relevant in the management of diabetic patients with heart disease (92.5% for TIR, 95% for GV, 97.5% for time spent in hypoglycaemia) and can improve the prognosis of those with ischaemic heart disease (100% for hypoglycaemia, 90% for hyperglycaemia) or with heart failure (87.5% for hypoglycaemia, 85% for TIR, 87.5% for GV). The experts retained that CGM can be used and can impact the short- and long-term prognosis during an acute cardiovascular event. Lastly, CGM has a recognized educational role for diabetic subjects.

Conclusions. According to this Delphi consensus, the clinical and prognostic use of CGM in diabetic patients at high cardiovascular risk is promising and deserves dedicated studies to confirm the experts’ feelings.

Background

Self-monitoring of blood glucose (SMBG) has until now been the most widely used method by patients with diabetes to assess their own glycaemia and guide diabetes treatment. On the other hand, glycated haemoglobin A1c (HbA1c) is the primary tool for assessing glycaemic control and has a strong predictive value for diabetes complications (1–6). However, both these established methods of diabetes assessment present well-known limitations. SMBG only provides data at a single point, is time consuming, inconvenient, and painful, often leading to poor adherence (7). HbA1c only reflects the average glycaemia of the last 3 months, is not reliable in the presence of some pathological conditions

such as anaemia and does not give information on blood glucose fluctuations caused by food intake, physical activity, medication or any other physical or emotional stress.

In the last decade techniques have been developed that allow continuous monitoring of blood glucose levels, which provide the unique opportunity to analyse in detail, even for several days, the glycaemic pattern (i.e., glucose levels and their variations) of diabetic patients (8).

Continuous glucose monitoring (CGM) devices use a fixed sensor with a subcutaneous glucose-oxidase platinum electrode that measures glucose concentrations in the interstitial fluids (9). They either continuously track the glucose concentration providing real-time data, namely real-time CGM (rtCGM), or show continuous measurements intermittently scanned “on-demand”, namely intermittently scanned CGM (isCGM) or flash glucose monitoring (FGM) (10).

CGM provides several new parameters (“glucometrics”) that may better reflect patients’ glycaemic values and consensually improve their treatment. Importantly, some data suggest that the management of diabetic patients by CGM might also improve clinical outcome and reduce the risk of complications (10). The most important of the glucometrics derived from CGM include the time in range (TIR), defined as the time with glycaemia fitting among two cut-offs of 70 and 180 g/dL (11), and glycaemic variability (GV), which reflects the amplitude and the frequency of glycaemic fluctuations (12, 13). CGM derived glucometrics overcome the main issues related to SMBG and HbA1c providing novel, easy-to-get and unpainful data about glucose fluctuations, including the detection of relevant hyperglycaemic and, even more, hypoglycaemic events (13), which have consistently been associated with a worse clinical outcome in diabetic patients (14).

Taken together, these considerations let a recent consensus of diabetologists acknowledge the obsolescence of SMBG and limitations of HbA1c, highlighting the need of using new tools and glucometrics to improve glycaemic control and therapeutic management (15). Moreover, CGM has been gradually improved in terms of easiness to use, accuracy, reliability, and cost effectiveness. Accordingly, the American Diabetes Association (ADA) has recently recommended its use for the management of both patients with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus treated with multiple daily insulin injections (16).

Notably, the recent publication of randomized clinical trials (RCT) showing improved cardiovascular (CV) outcome in diabetic patients treated with some new anti-hyperglycaemic agents (17) has raised cardiologists’ interest towards appropriate treatment of diabetes and stimulated new relations between cardiologists and diabetologists. However, it seems now necessary to extend to the cardiologists the knowledge of CGM and new glucometrics, letting them provide this diagnostic option to achieve a better glycaemic control in their diabetic patients with high CV risk or overt heart disease. However, several uncertainties and lack of evidence exist in this field.

Considering this background, the purpose of this study was to perform a Delphi survey among a panel of Italian diabetologists and cardiologists to gather an expert consensus on the use of CGM in diabetic

patients at high CV risk or with a history of CV events.

Methods

The Delphi method is a structured technique aimed at obtaining, by repeated rounds of questionnaires, a consensus opinion from a panel of experts in areas where evidence is scarce, and opinion is important (18–20). In the present study, the consensus process consisted of a double-step web-based Delphi method, which took place between May and September 2021.

The online survey was developed by a panel of six physicians (three couples of diabetologists-cardiologists from three Italian excellence centres), identified here as key opinion leaders (KOLs) in their respective field in Italy. The KOLs virtually met to fully analyse the published literature and discuss the unmet needs about the topic. Hence, they identified 22 statements, which were in serious need of clarification and debate, all focused on CGM use: type of patients who can benefit from CGM, prognostic impact of CGM in diabetic patients with heart disease, CGM use during acute CV events, educational issues of CGM (Table 1).

Table 1
The survey.

Statement 1: Type of patients who can benefit from continuous glucose monitoring (<i>flash</i> and <i>classic CGM</i>)	
1.1	Based on the data available to date, continuous glucose monitoring can represent a valid prognostic tool in every person affected by diabetes mellitus
1.2	Continuous glucose monitoring is prognostically useful in patients with type 1 diabetes and in
1.3	patients with type 2 diabetes on multiple daily insulin injections
1.4	Continuous glucose monitoring in type 2 diabetes treated with basal insulin and/or oral hypoglycaemic agents and/or other injecting drugs is useful in clinical characterization of the
1.5	patient and in making treatment decisions (e.g., to monitor change of therapy)
1.6	Continuous glucose monitoring is particularly useful in patients with physical limitations that prevent blood glucose measurement with the traditional capillary test (e.g., severe arthritis, Parkinson's disease, other)
	Continuous glucose monitoring is useful in patients in whom a rapid improvement in blood glucose control is clinically indicated (e.g., post-myocardial infarction, pre-/post-surgery, sepsis, acute respiratory failure, acute renal failure)
	Continuous glucose monitoring facilitates telemonitoring in elderly patients
Statement 2: Prognostic impact of continuous glucose monitoring in diabetic patients affected by heart disease	
2.1	The time-in-range (percentage of monitoring time with blood glucose values between 70 and 180 mg/dL) is a parameter that provides more complete and detailed information than HbA1c
2.2	in the clinical evaluation of people with diabetes
2.3	The reduction in hypoglycaemic episodes improves the prognosis of diabetic patients with ischemic heart disease
2.4	The reduction of hyperglycaemic episodes improves the prognosis of diabetic patients with
2.5	ischemic heart disease
2.6	Time-in-range is an important element for therapeutic optimization in the diabetic patient with heart disease
2.7	The time spent in hypoglycaemia is an important element for therapeutic optimization in the
2.8	diabetic patient with heart disease
2.9	Glycaemic variability is an important element for therapeutic optimization in the diabetic patient with heart disease
	Time-in-range has a prognostic role in the diabetic patient with heart failure
	Time spent in hypoglycaemia has a prognostic role in the diabetic patient with heart failure
	Glycaemic variability has a prognostic role in the diabetic patient with heart failure
Statement 3: Use during acute cardiovascular events	

Statement 1: Type of patients who can benefit from continuous glucose monitoring (<i>flash</i> and <i>classic</i> CGM)	
3.1	Continuous glucose monitoring can be easily used in coronary care unit/intensive care unit
3.2	Reduction in hypoglycaemic episodes improves short-term prognosis during an acute cardiovascular event
3.3	Reduction in hyperglycaemic episodes improves short-term prognosis in patients with an acute cardiovascular event
3.4	The optimization of time-in-range and glycaemic variability and the reduction of time in hypoglycaemia are associated with an improvement in the long-term prognosis in patients with an acute cardiovascular event
Statement 4: Insulin/hypoglycaemia education	
4.1	Continuous glucose monitoring helps patients with diabetes mellitus improve the perception of their disease
4.2	Continuous glycaemic monitoring can be helpful in reducing hypoglycaemic episodes
4.3	The possibility to use alarms, now available in all interstitial glucose sensors, helps prevent hypoglycaemias

Once developed, the survey was evaluated by 6 external validators chosen by the panel to test its understandability and clarity. Following this, the questionnaire was distributed to 21 couples of expert diabetologists-cardiologists via an online survey platform with anonymized results. The experts were clinicians with solid experience in their respective field, selected throughout the country among Unit directors, University professors and national and international Scientific Societies members, so that the whole country was homogeneously represented (19).

Diabetologists and cardiologists were asked to express their level of agreement or disagreement with each statement on a 5-point Likert scale, scored as follows: 1, extremely disagree; 2, disagree; 3, agree; 4, mostly agree; and 5, extremely agree. All answers were categorized into two categories: for the purpose of this study, “extremely disagree” and “disagree” were categorized into category “Negative Consensus”; “agree”, “mostly agree” and “extremely agree” were categorized into “Positive Consensus”. A cut-off of 66% of agreement/disagreement was chosen *a priori* to represent positive or negative consensus, respectively. No consensus was reached when < 66% of the answers fell in the same category (19, 20). There was no need to re-rate any statement since every declaration reached consensus at the first round.

Descriptive statistics were used to summarize the results. A sub-analysis of the results according to the area of expertise (diabetology vs cardiology) was also provided.

The study is based on a survey that does not involve the participation of human subjects nor patient data management and does not aim to modify the current clinical practice of participants. Consequently, this study did not require ethical approval. All experts involved in the Delphi survey were informed of the

study's objectives and the possibility of publishing the results in a peer-reviewed article. The participation was voluntary. They expressed their consent to participate in the survey after logging into the secure online survey platform via credentials, by actively clicking on the appropriate box.

Results

In the first round of the Delphi survey, there were 40 respondents out of 42 invited in the expert group (95%), equally divided according to the two specialties. Thirty-two (80%) of the respondents were males and eight (20%) females, with a nationwide homogeneous distribution (52.5% from the North-Centre of Italy, 47.5% from South-Centre of Italy) (Fig. 1). The clinical experience and the professional role of the respondents is detailed in Table 2, with 88% of them working for > 25 years and 60% of them > 30 years. The panel represented 32 national and international Scientific Societies.

Table 2
Clinical experience and professional role of the respondents.

Characteristic	Frequency (n = 40)
Clinical experience (years):	
- 10–19	1 (2.5%)
- 20–25	4 (10.0%)
- 26–30	11 (27.5%)
- 31–35	9 (22.5%)
- 36–40	10 (25.0%)
- >40	5 (12.5%)
Unit director	39 (97.5%)
Academic role:	
- Full professor	19 (47.5%)
- Associate professor	8 (20.0%)
- Professor on contract	5 (12.5%)
- PhD	1 (2.5%)

In round 1, a positive consensus was reached for 21/21 statements (100%). Table 3 summarizes the statements and presents the percentage of agreement/disagreement for each one based on the responses of the 40 panellists. Major statements, grouped for macro-areas, are reported below.

Type of patients who can benefit from continuous glucose monitoring (FGM and rtCGM)

The experts strongly agreed that CGM is a prognostic tool for T1DM and T2DM treated with multiple daily insulin injections (90%), and, to a lesser extent, for every diabetic patient (70%). Moreover, they firmly believe that CGM is clinically useful to better characterize patients independently from the anti-hyperglycaemic agent(s) they are taking (88%), for patients with physical limitations preventing the correct use of the capillary test (93%), in the acute setting (93%), and as a valid tool for remote monitoring for elderly subjects (95%).

Prognostic impact of continuous glucose monitoring in diabetic patient affected by heart disease

A full positive consensus was reached considering that the reduction of hypoglycaemic episodes improves the prognosis in patients with ischaemic heart disease (100%), but also hyperglycaemic episodes are similarly perceived (90%). The experts strongly retain that TIR provides more complete and detailed information than HbA1c in the clinical evaluation of people with diabetes (93%), and that it represents a useful tool for optimization of treatment in those with heart disease (93%). The consensus, even to a greater extent, was also obtained for the time spent in hypoglycaemia (98%) and for GV (95%) in diabetic patients with heart disease.

A positive, but less strong, consensus was also reached in the field of heart failure (HF) as regards the prognostic role of TIR (85%), time spent in hypoglycaemia (88%) and GV (88%).

CGM use during acute cardiovascular events

According to the expert panel, CGM can be easily used in coronary care unit or intensive care unit (93%). In the setting of acute CV events, the experts fully agreed that the reduction of hypoglycaemic episodes improves the short-term prognosis (100%) as well as for the reduction of hyperglycaemic episodes (90%). In addition, they also agreed that the optimization of TIR and GV and the reduction of the time spent in hypoglycaemia can improve the long-term prognosis (93%).

Insulin/hypoglycaemia education

A full positive consensus was obtained in considering CGM helpful for patients with diabetes to improve the perception of the disease (100%) and to reduce the hypoglycaemic episodes (100%), also thanks to the possibility to set alarms to prevent them (95%).

Discussion

CGM is currently recommended and reimbursed by the Italian National Health Service for the management of patients with T1DM and T2DM treated with multiple daily insulin injections (16). However, a growing need is felt by Italian experts to extend its use to patients with T2DM, regardless diabetes treatment, with special needs or at high risk of complications. Indeed, quantifying the duration and magnitude of glycaemic excursions provides another means of assessing glucose control, which is perceived by the panel as complementary and more complete than SMBG and HbA1c (10). Blood glucose is a vital parameter that in physiology changes in relation to meals, physical activity and all conditions

that generate stress; in pathological conditions, such as in people with diabetes, glycaemia also changes with therapies, particularly those that can lead to severe reductions such as insulin. GV is a process characterized by amplitude, frequency, and duration of the fluctuations. Consequently, GV is directly related to hypoglycaemic and hyperglycaemic episodes, as well as their duration and TIR (21). It is well known that GV is an independent risk factor for diabetes complications, including cardiovascular diseases, acting through the oxidative stress pathway (22–26), and has effects on cognitive function and quality of life (27). Moreover, increased GV is strongly associated with mortality in the intensive care setting (28, 29). Furthermore, the objective of diabetes control is to keep blood glucose levels into an accepted range, since deviations from the range in both directions are harmful, increasing the risk of complications with the amplitude of the deviations. Two large randomized controlled trials have demonstrated a significant reduction of hypoglycaemic events and GV, as well as increase in TIR and patients' satisfaction in subjects with T1DM (30) and insulin treated T2DM (31) managed with FGM, as compared to SMBG. In addition, real-world studies showed greater reductions in HbA1c levels using FGM compared to SMBG (32, 33), also showing that the number of glucose scans is inversely associated with time spent in hypoglycaemia or hyperglycaemia and is positively correlated with TIR (34). Consequently, besides hypoglycaemic, and hyperglycaemic episodes, according to the panel, also GV and TIR should now be assessed as part of the routine management of diabetes (10). In this regard, given the evidence reported above, the experts believed that CGM can have a prognostic role in patients for whom it is recommended by guidelines and reimbursed by the Italian NHS, but also to other to whom the recommendation may be extended.

Diabetes is a traditional risk factor for CV disease, carrying a higher risk for sudden cardiac death, accelerated atherosclerosis, ischaemic heart disease, cardiomyopathy, and HF (35). In addition, oscillating glucose is considered to have more deleterious effects than constant high glucose levels on endothelial function (36) and postprandial glycaemic spikes may be a more robust determinant of CV disease risk than average glucose levels (37). This is explained by the hyperglycaemia-induced activation of oxidative stress pathways and inflammation as well as by the rapid formation of advanced glycosylated end-products (AGEs) (38). However, a doubtful reduction of coronary artery disease by glucose-lowering treatment was found in large meta-analyses (39, 40), possibly because the benefits were partly counterweighed by an increased occurrence of severe hypoglycaemic episodes, associated with the intensive insulin therapy. In fact, hypoglycaemia can be associated with the development of adverse CV outcomes by means of several mechanisms, including blood coagulation abnormalities, inflammation, endothelial dysfunction, and sympathetic responses (35, 41). Accordingly, the panel agreed that CGM with the new glucometrics may have a prognostic role in patients with ischaemic heart disease. Notably, although to a lesser extent than hypoglycaemia, also hyperglycaemic episodes are perceived as prognostically deleterious by the panel.

Diabetes is also a risk factor for HF (42) and left ventricular dysfunction can be found in up to 40% of diabetic people (43). The link between the two conditions goes beyond ischemic heart disease, but also involves several other mechanisms, including micro-circulatory dysfunction, metabolic derangements with lipotoxicity, cytokine and renin–angiotensin–aldosterone system activation, altered calcium

handling, and endothelial dysfunction (44, 45). Oxidative stress and inflammation seem to be at the basis of the phenomenon and are also the hallmark of HF with preserved ejection fraction, as currently hypothesized (46, 47). Finally, also diabetic neuropathy and consequently cardiac autonomic dysfunction can play a role in this context (48). The interest about the link between HF and diabetes is recently growing in the cardiologic scenario after the publication of SGLT2 inhibitors trials, which demonstrated beneficial effects of these drugs in HF patients, which was in fact independent from diabetes itself (49, 50). The panel agreed in considering hypoglycaemic events, TIR and GV as having a prognostic role in HF patients with diabetes, even if dedicated studies are still lacking. This perception should prompt future research in this field.

Mortality in acute myocardial infarction and other acute CV events is also increased in patients with diabetes (51, 52). This may occur independently from the extent of myocardial infarct size, because of various negative effects, including increased inflammation, endothelial dysfunction, pro-thrombotic state and oxidative stress (52). Acute hyperglycaemia characterizes up to 50% of patients admitted for myocardial infarction (53), and for every 18 mg/dL (1 mmol/L) increase in glucose level above 200 mg/dL, it has been reported a 4% and a 5% increase in hospital mortality risk in patients without and with diabetes, respectively (54). In addition, impaired control of glycemia in this setting has been associated with severe coronary flow impairment, increased left ventricular dysfunction, larger infarct size, and higher risk of acute HF, cardiogenic shock, and acute kidney injury (53). On the other hand, also acute myocardial infarction patients with hypoglycaemia appear to have worse outcomes (55, 56), including myocardial ischaemia and arrhythmias (57). Furthermore, both hypoglycaemia and hyperglycaemia are associated with a three-fold increased risk of 30-day mortality when compared with euglycaemic patients, thus determining a U-shaped relationship between blood glucose levels and adverse outcomes (56). Consequently, the consensus is that both hyperglycaemia and hypoglycaemia should be avoided in critically ill patients (58). In fact, acute variability of glucose values negatively correlates with the proportion of reversibly injured myocardial tissue that does not progress to infarction (59). GV > 49 mg/dL was demonstrated to be the strongest independent predictor of mid-term major adverse cardiac events (death for cardiac cause, new-onset myocardial infarction, acute HF) (60). Finally, the experts agreed that the CGM can be useful in intensive care unit as it carries prognostic information at short-term (e.g., in-hospital mortality). In addition, the improvement in TIR, GV and time spent in hypoglycaemia is perceived to also improve the long-term prognosis of an acute CV event, even if specific data are lacking.

CGM use was demonstrated to improve patients' quality of life, with a greater satisfaction than SMBG (30, 31, 61). In fact, according to the expert panel, the system has an educational aspect, helping patients' perception of their own disease and increasing the adherence and the confidence to treatment. Notably, CGM reduces hypoglycaemic episodes, which are most feared therapy complication (30, 31), particularly by the activation of dedicated alarms in the more recent systems, which can help preventing them.

Conclusions

The results of this Delphi survey suggest that the use of CGM systems may have an important clinical and prognostic role in patients with diabetes beyond the current recommendations. In particular, the wealth of data provided by CGM devices, the availability of new glucometrics, patients' satisfaction, the suggested improvement of clinical outcomes and the possibility of remote monitoring, thanks to in cloud platforms, are key elements favouring CGM use in patient at risk or with overt CV disease, particularly in those with ischaemic heart disease and HF, both in the chronic and acute setting. Dedicated studies are needed, however, to confirm the experts' feelings.

Abbreviations

CGM: continuous glucose monitoring

TIR: time in range

GV: glycaemic variability

HbA1c: glycated haemoglobin A1c

SMBG: self-monitoring blood glucose

ADA: American Diabetes Association

T1DM: type 1 diabetes mellitus

T2DM: type 2 diabetes mellitus

CV: cardiovascular

CVOT: cardiovascular outcome trial

KOL: key opinion leader

HF: heart failure

Declarations

- Ethics approval and consent to participate: The study is based on a survey that does not involve the participation of human subjects nor patient data management and does not aim to modify the current clinical practice of participants. Consequently, this study did not require ethical approval.
- Consent for publication: Not applicable
- Availability of data and materials: The dataset supporting the conclusions of this article is available and included within the article.
- Competing interests: all authors report personal fees from Abbott Diabetes Care, during the conduct of the study. S.G. reports personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hikma

Pharmaceuticals, Merck Sharp & Dhome, Molteni Farmaceutici, Novartis, Novo Nordisk, Sanofi, Takeda, Teva, Zentiva, outside the submitted work; .

- Funding: This study was supported by Abbott Diabetes Care
- Authors' contributions: E.S. wrote the paper and prepared tables and figures. All authors reviewed the manuscript
- Acknowledgements:

External Validators:

Flavia Caniato, Firenze

Nicola Cosentino, Milano

Ilaria Dicembrini, Firenze

Priscilla Lamendola, Roma

Alessandro Rizzi, Roma

Maurizio Rondinelli, Milano

Delphi Expert Panel Group:

Angelo Avogaro, Padova

Federico Bertuzzi, Milano

Enzo Bonora, Verona

Claudio Borghi, Bologna

Raffaella Buzzetti, Roma

Stefano Carugo, Milano

Davide Capodanno, Catania

Agostino Consoli, Chieti

Antonio Conti, Milano

Rossella Danesi, Brescia

Paolo Di Bartolo, Ravenna

Gaetano Maria De Ferrari, Torino

Stefano Favale, Bari

Carlo Giorda, Torino

Francesco Giorgino, Bari

Angela Girelli, Brescia

Paolo Golino, Napoli

Francesco Grigioni, Roma

Ciro Indolfi, Catanzaro

Concetta Irace, Catanzaro

Elisabetta Lovati, Pavia

Ada Maffettone, Napoli

Maria Masulli, Napoli

Fabrizio G. Oliva, Milano

Luigi Oltrona Visconti, Pavia

Emanuela Orsi, Milano

Uberto Pagotto, Bologna

Leonardo Paloscia, Chieti

Gianfranco Parati, Milano

Pasquale Perrone, Napoli

Gianfranco Piccirillo, Roma

Paolo Pozzilli, Roma

Giuseppe Pugliese, Roma

Francesco Purrello, Catania

Flavio Ribichini, Verona

Andrea Rubboli, Ravenna

Michele Senni, Bergamo

Roberto Trevisan, Bergamo

Claudio Tubili, Roma

Massimo Uguccioni, Roma

References

1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993 Sep 30;329(14):977-86.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998 Sep 12;352(9131):837-53.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998 Sep 12;352(9131):854-65. Erratum in: *Lancet* 1998 Nov 7;352(9139):1558.
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med.* 2000 Feb 10;342(6):381-9.
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA.* 2002 May 15;287(19):2563-9.
6. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. *Diabetes Care.* 2016 May;39(5):686-93.
7. Moström P, Ahlén E, Imberg H, Hansson PO, Lind M. Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. *BMJ Open Diabetes Res Care.* 2017 Apr 6;5(1):e000342.
8. Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. *Diabetes Care.* 2017 Dec;40(12):1614-1621.
9. Patton SR, Clements MA. Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Children with Type 1 Diabetes- Are there Pros and Cons for Both? *US Endocrinol.* 2012 Summer;8(1):27-29.

10. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*. 2017 Dec;40(12):1631-1640.
11. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovic K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019 Aug;42(8):1593-1603.
12. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. *Lancet Diabetes Endocrinol*. 2019 Mar;7(3):221-230.
13. Ajjan R, Slattery D, Wright E. Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. *Adv Ther*. 2019 Mar;36(3):579-596.
14. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. *Diabetes Care*. 2012;35:1897–901.
15. Bruttomesso D, Laviola L, Avogaro A, Bonora E, Del Prato S, Frontoni S, Orsi E, Rabbone I, Sesti G, Purrello F; of the Italian Diabetes Society (SID). The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method. *Nutr Metab Cardiovasc Dis*. 2019 May;29(5):421-431.
16. American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021 Jan;44(Suppl 1):S85-S99.
17. Ahmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. *Eur Cardiol*. 2021 Mar 30;16:e11.
18. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs*. 2000 Oct;32(4):1008-15.
19. Giannarou L, Zervas E. Using Delphi technique to build consensus in practice. *Int J Bus Sci Appl Manage*. 2014;9:65–82.
20. Walker A, Selfe J. The Delphi method: a useful tool for the allied health researcher. *Br J Therapy and Rehabilitation*. 1996;3:677–81.
21. Kovatchev BP, Flacke F, Sieber J, Breton MD. Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data. *Diabetes Technol Ther*. 2014 May;16(5):303-9.
22. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting

- glucose or HbA1c level. *Diabetes Care*. 2000 Dec;23(12):1830-4.
23. Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. *Circulation*. 2001 Jan 23;103(3):346-7.
 24. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. *Circulation*. 2004 Jul 13;110(2):214-9.
 25. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*. 2006 Apr 12;295(14):1681-7.
 26. Martinez M, Santamarina J, Pavesi A, Musso C, Umpierrez GE. Glycemic variability and cardiovascular disease in patients with type 2 diabetes. *BMJ Open Diabetes Res Care*. 2021 Mar;9(1):e002032.
 27. Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. *J Clin Endocrinol Metab*. 1994 Dec;79(6):1659-62.
 28. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. *Anesthesiology*. 2006 Aug;105(2):244-52.
 29. Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. *Intensive Care Med*. 2011 Apr;37(4):583-93.
 30. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *Lancet*. 2016 Nov 5;388(10057):2254-2263.
 31. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. *Diabetes Ther*. 2017 Feb;8(1):55-73.
 32. Krakauer M, Botero JF, Lavallo-González FJ, Proietti A, Barbieri DE. A review of flash glucose monitoring in type 2 diabetes. *Diabetol Metab Syndr*. 2021 Apr 9;13(1):42.
 33. Evans M, Welsh Z, Ells S, Seibold A. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. *Diabetes Ther*. 2020 Jan;11(1):83-95.
 34. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. *Diabetes Res Clin Pract*. 2018 Mar;137:37-46.
 35. Abuelgasim E, Shah S, Abuelgasim B, Soni N, Thomas A, Elgasim M, Harky A. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death. *Rev Cardiovasc Med*. 2021 Jun 30;22(2):301-314.

36. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes*. 2008 May;57(5):1349-54.
37. Hanssen NMJ, Kraakman MJ, Flynn MC, Nagareddy PR, Schalkwijk CG, Murphy AJ. Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes? *Front Cardiovasc Med*. 2020 Sep 18;7:570553.
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001 Dec 13;414(6865):813-20.
39. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009 May 23;373(9677):1765-72.
40. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2011 Jul 26;343:d4169.
41. Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. *Circulation*. 2015 Dec 15;132(24):2345-50.
42. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation*. 2008 May 13;117(19):2544-65.
43. Poulsen MK, Henriksen JE, Dahl J, Johansen A, Gerke O, Vach W, Haghfelt T, Høilund-Carlsen PF, Beck-Nielsen H, Møller JE. Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. *Circ Cardiovasc Imaging*. 2010 Jan;3(1):24-31.
44. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. *JACC Heart Fail*. 2015 Feb;3(2):136-45.
45. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. *Eur J Heart Fail*. 2017 Jan;19(1):43-53.
46. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular

- endothelial inflammation. *J Am Coll Cardiol*. 2013 Jul 23;62(4):263-71.
47. Paulus WJ. Unfolding Discoveries in Heart Failure. *N Engl J Med*. 2020 Feb 13;382(7):679-682.
48. Tremamunno S, De Vita A, Villano A, Melita V, Ingrasciotta G, Ruscio E, Filice M, Bisignani A, Ravenna SE, Tartaglione L, Rizzo GE, Di Leo M, Felici T, Pitocco D, Lanza GA. Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2021 Jul 8:e3484. doi: 10.1002/dmrr.3484. Epub ahead of print.
49. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Oct 8;383(15):1413-1424.
50. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozd J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21;381(21):1995-2008.
51. Rousan TA, Pappy RM, Chen AY, Roe MT, Saucedo JF. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). *Am J Cardiol*. 2014 Oct 15;114(8):1136-44.
52. Marenzi G, Cosentino N, Genovese S, Campodonico J, De Metrio M, Rondinelli M, Cornara S, Somaschini A, Camporotondo R, Demarchi A, Milazzo V, Moltrasio M, Rubino M, Marana I, Grazi M, Lauri G, Bonomi A, Veglia F, De Ferrari GM, Bartorelli AL. Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. *Diabetes Care*. 2019 Jul;42(7):1305-1311.
53. Marenzi G, De Metrio M, Rubino M, Lauri G, Cavallero A, Assanelli E, Grazi M, Moltrasio M, Marana I, Campodonico J, Discacciati A, Veglia F, Bartorelli AL. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. *Am Heart J*. 2010 Dec;160(6):1170-7.
54. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, Visser FC. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. *Arch Intern Med*. 2004 May 10;164(9):982-8.
55. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, Spertus JA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *JAMA*. 2009 Apr 15;301(15):1556-64.

56. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM; TIMI Study Group. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2005 Jul 5;46(1):178-80.
57. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. *Diabetes*. 2014 May;63(5):1738-47.
58. Mesotten D, Preiser JC, Kosiborod M. Glucose management in critically ill adults and children. *Lancet Diabetes Endocrinol*. 2015 Sep;3(9):723-33.
59. Teraguchi I, Imanishi T, Ozaki Y, Tanimoto T, Kitabata H, Ino Y, Ishibashi K, Komukai K, Hirata K, Akasaka T. Impact of stress hyperglycemia on myocardial salvage following successfully recanalized primary acute myocardial infarction. *Circ J*. 2012;76(11):2690-6.
60. Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, Douard H, Ouattara A, Catargi B. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome. *Diabetes Care*. 2019 Apr;42(4):674-681.
61. Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. *Diabetes Care*. 2019 Jul;42(7):1178-1184.

Table

Table 3 is available in the Supplementary Files section

Figures



Figure 1

Geographic distribution of the respondents.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TABLE3new.tif